Tuesday, August 21, 2018
News

Cipla gets USFDAs final approval for generic Isuprel

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Mumbai | Thursday, Jun 14 2018 IST
Cipla, announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, single-usesterile Ampoule from the United States Food and Drug Administration (US FDA).

Cipla's Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, ampoule is APrated generic therapeutic equivalent version of Hospira Inc's Isuprel Injection, 0.2mg/ml, Cipla said in a filing with BSE.

Isoproterenol Hydrochloride are indicated for the treatment of Mild or transient episodes of heart block that do not require electric shock or pacemaker therapy.

It is also used As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock.

According to IQVIA (IMS Health), Isuprel Injection and its generic equivalents had US sales of approximately USD 148M for the 12-month period ending April 2018, the filing added.

UNI JS AE 1455

-- (UNI) -- C-1-DL0169-1402440.Xml

Loading...
 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
TRENDING TOPICS
 
 
 
CITY NEWS
MORE CITIES
INDIA WORLD ASIA
Google Doodle marks author Ismat Chughta...
Tripura to donate Rs 1 cr for flood-hit ...
Amarnath Yatra suspended for three days...
K'taka CM demands Rs 100 cr relief fund ...
SC judges to contribute to Kerala flood ...
Kerala CM urges Centre for additional he...
More...    
 
 Top Stories
Venezuelans flee to Brazil amid eco... 
2 Soldiers, 5 civilians killed in R... 
Trump 'most likely' to meet Kim aga... 
Chinese shares open higher... 
Shooting 'Destination Wedding' was ... 
Pak federal cabinet to put Sharif o... 
Australian PM survives leadership v... 
World Senior Citizens Day: AMD, lea...